The Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, which presented a replacement treatment in 2019, demonstrated the effectiveness of a sodium-glucose cotransporter-2 (SGLT2) inhibitor against DKD. Here, SLC5A2 is linked to Nephropathy.